Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3).
Loading...
ICR Authors
Authors
Popat, S
Liu, G
Lu, S
Song, G
Ma, X
Yang, JC-H
Liu, G
Lu, S
Song, G
Ma, X
Yang, JC-H
Document Type
Journal Article
Date
Date Accepted
2021-07-22
Date Available
2022-01-17T09:49:04Z
Abstract
Crizotinib is highly efficacious and more tolerable than chemotherapy for ALK<sup>+</sup> non-small-cell lung cancer (NSCLC), but its progression-free survival benefit and intracranial efficacy have limitations. Head-to-head comparisons of next-generation ALK inhibitors in patients with ALK<sup>+</sup> NSCLC progressing on crizotinib will contribute toward optimizing survival. This international, Phase III, randomized, open-label study (ALTA-3) will therefore assign patients with locally advanced or metastatic ALK<sup>+</sup> NSCLC progressing on crizotinib to receive either brigatinib 180 mg qd (7-day lead-in at 90 mg qd) or alectinib 600 mg twice daily. The primary end point is progression-free survival as assessed by a blinded Independent Review Committee; the key secondary end point is overall survival. Clinical trial registration number: NCT03596866 (ClinicalTrials.gov).
Citation
Future oncology (London, England), 2021, 17 (32), pp. 4237 - 4247
Source Title
Publisher
ISSN
1479-6694
eISSN
1744-8301
Collections
Research Team
Thoracic Oncology